I ask because I'm seeing a mix of answers for this kind of scenario.

RIGL has a very positive future ahead itself given it's latest developments in medicine. Part of their success comes from their “Strategic Collaboration” with Eli Lilly that started in 2021. As of December 2022, there are a few hints that came up that may suggest an possible acquisition of RIGL. If this is true, how this would this impact RIGL's stock price upon being acquired?

Some of these hints include:

• Latest SI report for RIGL show it lowering from 2.5% to .05%.
  • RIGL was at 0.80 cents when short-sellers decided to buy back–which is an odd. Normally, when a company isn't showing much promise for the future and the stock is at 0.80 cents a share, short-sellers would borrow anything and everything they can to bring the price to zero. However, for RIGL, we're not seeing that. We're seeing the opposite.
• Both RIGL and Eli Lilly were removed from the ETF XBI and LABU.
• Shares of RIGL moved into acquisition vehicles by State Street.
• Eli has the capital to acquire RIGL.